Literature DB >> 17684290

Role of CD4+ T cells in sarcoidosis.

Johan Grunewald1, Anders Eklund.   

Abstract

Activated pulmonary CD4(+) T lymphocytes of the Th-1 type are essential for the inflammatory process in sarcoidosis, and IFN-gamma production is crucial for the characteristic granuloma formation. Both the T cells and their inflammatory mediators may constitute possible targets for immunotherapy. A particular T-cell subset, the T-cell receptor (TCR) AV2S3(+) bronchoalveolar lavage (BAL) CD4(+) T cells, is found at dramatically increased levels in the BAL fluid of human leukocyte antigen (HLA)-DRB1*0301-positive and/or HLA-DRB3*0101-positive patients with sarcoidosis. The AV2S3(+) BAL CD4(+) T cells strongly associate with the sarcoid inflammation, and future studies on this particular T-cell subset to reveal their specificity may lead to the identification of sarcoidosis-specific antigen(s). T-cell subpopulations with regulatory functions (i.e., natural killer T cells and T regulatory cells) have recently been described as abnormal in sarcoidosis. Dysfunctional regulatory T cells may allow T effector cells to contribute to the formation of granulomas, and they may thus be relevant for the inflammatory process in this disease. These findings are exciting news and will be of help in designing new treatment strategies.

Entities:  

Mesh:

Year:  2007        PMID: 17684290      PMCID: PMC2647597          DOI: 10.1513/pats.200606-130MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  42 in total

1.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

2.  Specific bronchoalveolar lavage fluid T cells associate with disease in a pair of monozygotic twins discordant for sarcoidosis.

Authors:  I Grunewald; A Eklund
Journal:  J Intern Med       Date:  2001-12       Impact factor: 8.989

3.  Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.

Authors:  S Sharif; G A Arreaza; P Zucker; Q S Mi; J Sondhi; O V Naidenko; M Kronenberg; Y Koezuka; T L Delovitch; J M Gombert; M Leite-De-Moraes; C Gouarin; R Zhu; A Hameg; T Nakayama; M Taniguchi; F Lepault; A Lehuen; J F Bach; A Herbelin
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

4.  Lung restricted T cell receptor AV2S3+ CD4+ T cell expansions in sarcoidosis patients with a shared HLA-DRbeta chain conformation.

Authors:  J Grunewald; J Wahlström; M Berlin; H Wigzell; A Eklund; O Olerup
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

5.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.

Authors:  K Miyamoto; S Miyake; T Yamamura
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.

Authors:  David G Morris; Robert M Jasmer; Laurence Huang; Michael B Gotway; Stephen Nishimura; Talmadge E King
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

7.  Markers of activity in clinically recovered human leukocyte antigen-DR17-positive sarcoidosis patients.

Authors:  A Planck; A Eklund; J Grunewald
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

8.  Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis.

Authors:  Seiichiro Kobayashi; Yoshikatsu Kaneko; Ken-Ichiro Seino; Yoshihito Yamada; Shinichiro Motohashi; Junzo Koike; Kaoru Sugaya; Takayuki Kuriyama; Shigetaka Asano; Tomiyasu Tsuda; Hiroshi Wakao; Michishige Harada; Satoshi Kojo; Toshinori Nakayama; Masaru Taniguchi
Journal:  Int Immunol       Date:  2004-02       Impact factor: 4.823

9.  T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis.

Authors:  Anders Planck; Kianoosh Katchar; Anders Eklund; Sofia Gripenbäck; Johan Grunewald
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2003-06       Impact factor: 0.670

10.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

View more
  37 in total

1.  Antifibrotic role of HGF in sarcoidosis.

Authors:  Martin Faehling; Martin Hetzel; Diana Anders; Gerlinde Trischler; Max Bachem
Journal:  Lung       Date:  2012-02-05       Impact factor: 2.584

2.  Identification of apolipoprotein A-I in BALF as a biomarker of sarcoidosis.

Authors:  Yoshihisa Nukui; Yasunari Miyazaki; Kozo Suhara; Tsukasa Okamoto; Haruhiko Furusawa; Naohiko Inase
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

3.  A case of Graves' disease developing with exacerbation of sarcoidosis.

Authors:  Shinya Makino; Chisako Yagi; Mariko Naka; Sachie Hirose; Masayoshi Fujiwara; Chiho Ohbayashi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

4.  M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis.

Authors:  Stefan Prokop; Frank L Heppner; Hans H Goebel; Werner Stenzel
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 5.  The potential of the immunological markers of sarcoidosis in exhaled breath and peripheral blood as future diagnostic and monitoring techniques.

Authors:  Hasib Ahmadzai; Denis Wakefield; Paul S Thomas
Journal:  Inflammopharmacology       Date:  2011-02-13       Impact factor: 4.473

Review 6.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

7.  Granulomatous disease in common variable immunodeficiency.

Authors:  Omür Ardeniz; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2009-08-28       Impact factor: 3.969

8.  ApoE-deficient mice on cholate-containing high-fat diet reveal a pathology similar to lung sarcoidosis.

Authors:  Andriy O Samokhin; Frank Bühling; Franz Theissig; Dieter Brömme
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

9.  Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.

Authors:  P Sakthivel; J Grunewald; A Eklund; D Bruder; J Wahlström
Journal:  Clin Exp Immunol       Date:  2015-11-24       Impact factor: 4.330

10.  Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101.

Authors:  Kyra Oswald-Richter; Hiroe Sato; Rana Hajizadeh; Bryan E Shepherd; John Sidney; Alessandro Sette; Lee S Newman; Wonder Puryear Drake
Journal:  J Clin Immunol       Date:  2009-06-18       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.